ArticleComputational and structural biotechnology journal2022
Exploring the active core of a novel antimicrobial peptide, palustrin-2LTb, from the Kuatun frog,
Article in Computational and structural biotechnology journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 17 citations in OpenAlex.
- Identification and Structure-Activity Relationship of a Novel Dermatoxin-like Antimicrobial Peptide with Partial LPS-Mediated Membrane Interaction.Molecules (Basel, Switzerland) · 2026Article
- Unstructured, disulfide-bridged C-terminus in helminth α-helical antimicrobial peptides enhances and modulates their activity.Scientific reports · 2026Article
- Adaptation of plateau frog peptide: From antimicrobial to angiogenic and proliferative functions.Journal of advanced research · 2026Article
- Differential membrane lipid disruption by lipopeptide antibiotics, colistin and turnercyclamycins.Nature communications · 2026Article
- Discovery and Optimisation of Novel Bombinin-Derived Peptides from Bombina variegata against Staphylococcus aureus.Probiotics and antimicrobial proteins · 2026Article
- Enhancing the selectivity and conditional sensitivity of an antimicrobial peptide through cleavage simulations and homoarginine incorporation to combat drug-resistant bacteria.Scientific reports · 2025Article
- Discovery, development and optimisation of a novel frog antimicrobial peptide with combined mode of action against drug-resistant bacteria.Computational and structural biotechnology journal · 2024Article
- Enhancement of Antimicrobial Function by L/D-Lysine Substitution on a Novel Broad-Spectrum Antimicrobial Peptide, Phylloseptin-TO2: A Structure-Related Activity Research Study.Pharmaceutics · 2024Article
- Small Natural Cyclic Peptides from DBAASP Database.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Progressive Design of a Ranatuerin-2 Peptide fromAntibiotics (Basel, Switzerland) · 2023Article
- Investigating antimicrobial peptide RI12 (K3W) as an effective bio-preservative against Listeria monocytogenes: a major foodborne pathogen.Archives of microbiology · 2023Article
- Membrane-Active Peptides and Their Potential Biomedical Application.Pharmaceutics · 2023Review
- A frog-derived antimicrobial peptide as a potential anti-biofilm agent in combating Staphylococcus aureus skin infection.Journal of cellular and molecular medicine · 2023Article
- Plectasin: from evolution to truncation, expression, and better druggability.Frontiers in microbiology · 2023Article
- A promising antibiotic candidate, brevinin-1 analogue 5R, against drug-resistant bacteria, with insights into its membrane-targeting mechanism.Computational and structural biotechnology journal · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial peptides (AMPs), one of the most promising next-generation antibiotics to address the problem of antibiotic-resistance, have gained increasing attention in recent decades. However, some bottlenecks, such as high manufacturing costs and high toxicity, have greatly hindered their development. To overcome these problems, we developed an efficient modification approach to find the valid active-core fragments of AMPs by mimicking the cleavage process of trypsin-like specificity proteases
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.